Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

BACKGROUND AND OBJECTIVES: Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed as an orally administered treatment for patients with moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders. These analyses characterized the population pharmacokinetics of upa...

Descripción completa

Detalles Bibliográficos
Autores principales: Klünder, Ben, Mittapalli, Rajendar K., Mohamed, Mohamed-Eslam F., Friedel, Anna, Noertersheuser, Peter, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614152/
https://www.ncbi.nlm.nih.gov/pubmed/30945116
http://dx.doi.org/10.1007/s40262-019-00739-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614152/
https://www.ncbi.nlm.nih.gov/pubmed/30945116
http://dx.doi.org/10.1007/s40262-019-00739-3

Ejemplares similares